Skip to main content
Vyome Holdings, Inc logo

Vyome Holdings, Inc — Investor Relations & Filings

Ticker · HIND ISIN · US67424L2097 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2024-09-24 Capital/Financing Update
Country US United States of America
Listing US HIND

About Vyome Holdings, Inc

https://www.reshapelifesciences.com/oba…

Vyome Holdings, Inc. is a clinical-stage biotechnology company focused on developing a portfolio of assets for immuno-inflammatory and potential orphan diseases. The company utilizes an artificial intelligence (AI)-driven platform to accelerate its research and development pipeline. Its operations are structured to leverage innovation and R&D capabilities across both the United States and India.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ReShape Lifesciences Inc. It reports a material event: a 1-for-58 reverse stock split of the company's common stock, effective September 23, 2024. The document includes details about the amendment to the Certificate of Incorporation to effect the reverse split, the impact on outstanding shares and securities, and a press release announcing the event. There are no financial statements or quarterly/yearly financial results presented. The primary content is an announcement of a capital structure change (reverse stock split). According to the filing definitions, updates on capital structure changes such as reverse stock splits fall under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the capital change, not just a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2024-09-24 English
425 Filing
Earnings Release Classification · 95% confidence The document is an earnings release issued by ReShape Lifesciences Inc. for the second quarter ended June 30, 2024. It includes detailed financial results such as revenue, gross profit, expenses, and cash position for the quarter and six months ended June 30, 2024. It also provides a corporate update including merger and asset purchase agreements, and announces a conference call to discuss these results. The document is filed pursuant to Rule 425 and Rule 14a-12, which are often used for merger-related communications, but the primary content is the financial results announcement. The presence of detailed financial data and operational highlights for the quarter indicates this is an Earnings Release (ER). It is not a full quarterly report (10-Q) or annual report (10-K), nor is it a proxy or merger filing. Therefore, the correct classification is Earnings Release (ER). The document length and content support a high confidence in this classification.
2024-08-28 English
425 Filing
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call for ReShape Lifesciences Inc. It includes detailed discussion of the company's financial results for the second quarter and six months ended June 30, 2024, including revenue, gross profit, expenses, and EBITDA. The presence of a Q&A style format with management commentary and financial performance review is typical of earnings call transcripts. The document also references the upcoming merger and strategic updates, which are commonly discussed in earnings calls. The document is not a formal earnings release (which would be a press release), nor is it an annual or interim report with full financial statements. It is not a regulatory filing or certification, nor a presentation or proxy material. Therefore, the correct classification is Call Transcript (CT). The confidence in this classification is very high given the explicit identification as an earnings call transcript and the content format.
2024-08-28 English
10-Q Filing
Interim / Quarterly Report Q2 2024
2024-08-14 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2024, by ReShape Lifesciences Inc. It announces the issuance of a press release containing financial results for the three and six months ended June 30, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 3852 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release of financial results without including the full report should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-08-14 English
4 Filing
Director's Dealing
2024-08-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.